Company ProfilePremium

ALTEOGEN Inc.

Company Profile Analysis

Ticker: 196170.KQ주식회사 알테오젠

ESOMAR 23 Corporate BadgeISO Certifications Badge
ALTEOGEN Inc. - Company showcase

Year Founded & Workforce

2008

30 Employees

ALTEOGEN Inc. logo

ALTEOGEN Inc. Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

ALTEOGEN Inc. Overview

Alteogen is a Daejeon-based biopharmaceutical platform company. It is one of only two companies in the world that has commercialised a recombinant human hyaluronidase able to turn intravenous (IV) biologics into subcutaneous (SC) injections. The other is Halozyme of the US. Alteogen's enzyme, ALT-B4 (berahyaluronidase alfa), comes from its Hybrozyme™ platform. It is co-formulated in Merck & Co.'s Keytruda Qlex™ / Keytruda SC, the first SC PD-1 inhibitor, which the FDA approved in September 2025.

Alteogen earns upfront payments, milestones, ALT-B4 supply revenue and royalties from ten global pharma licensees: MSD, Sanofi, Intas, Sandoz, Daiichi Sankyo, AstraZeneca, GSK/Tesaro, Biogen, an undisclosed partner and Novartis. Disclosed headline deal values total roughly KRW 16 trillion. The company also has biosimilars (Eylea biosimilar Eyluxvi®/Eyzenpi®, and a Herceptin biosimilar sold in China), a standalone hyaluronidase (Tergase®), ADC and long-acting platforms, and an early obesity candidate. Alteogen turned profitable in 2024. In 2025 it reported record revenue of KRW 215.9bn with a 49.5% operating margin.


Company self-description

In its press-release boilerplate and filings, Alteogen describes itself as a biopharmaceutical company that specialises in platform technologies for next-generation biologics. It names four areas:

  • Hybrozyme™, its human hyaluronidase platform for IV-to-SC conversion

  • NexP™ fusion technology, for long-acting biobetters

  • NexMab™, its antibody-drug conjugate (ADC) technology

  • Antibody biosimilars, developed in-house and with partners

The FY2025 earnings disclosure (27 February 2026) gave three reasons for record results. First, it recognised more revenue tied to Hybrozyme, including milestones from Keytruda SC's FDA and EMA approvals and the AstraZeneca upfront. Second, ALT-B4 supply sales grew. Third, royalties from the Herceptin biosimilar Anqutuo (安曲妥) in China increased.

Independent characterisation

Economically, Alteogen is a B2B enabling-technology licensor and specialty API supplier, with a small but growing product business attached.

Licensing. Partners pay Alteogen to co-formulate ALT-B4 with their own monoclonal antibodies, ADCs or other biologics. The goal is to deliver a large-volume SC dose in minutes instead of a 30–60 minute IV infusion. Merck's Keytruda Qlex is described as being given in about one minute. The licensor model has very high incremental margins: FY2025 gross margin was 76.7% and FY2025 operating margin was 49.5%.

Supply. Alteogen is contractually responsible for clinical and commercial supply of ALT-B4 to most licensees, including MSD, AstraZeneca, Tesaro, Intas and Sandoz. It currently uses outside contract manufacturers (CMOs), some overseas. A KRW 253.2bn in-house drug substance / drug product plant in Daejeon is due by September 2028.

Products. Alteogen sells Tergase® (recombinant human hyaluronidase) in Korea. It markets the aflibercept biosimilar ALT-L9 (approved in the EU as Eyluxvi® in September 2025 and in Korea as Eyzenpi®/아이젠피 in May 2026). It receives royalties on the trastuzumab biosimilar ALT-L2, which Qilu Pharmaceutical sells in China.

Pipeline optionality. Earlier-stage programmes include NexMab ADCs (ALT-P7), NexP long-acting proteins (ALT-P1, a long-acting growth hormone), and a new long-acting conjugate platform. The lead candidate on that platform is ALT-M5, a once-monthly incretin fusion protein for obesity.

Revenue model mix

Revenue streamNatureVisibility
Technical services / licensing (ALT-B4)Upfronts, option fees, development and regulatory milestones, sales milestones, royaltiesUpfronts are lumpy. Sales milestones and royalties now scale with Keytruda Qlex sales.
ALT-B4 supplyProduct revenue from enzyme supplied to licensees for clinical and commercial useGrows with partner volume
Merchandise and productsTergase®, ALT-L9 and other goods sold through the former Alteogen Healthcare / Alteogen Biologics channelsSmall so far
Other technical servicesRoyalties (e.g., Anqutuo in China) and service contractsRecurring, modest

A Butler summary of the H1 2026 semi-annual report gives the Q2 2026 revenue mix as about 88% ALT-B4 technical services, about 9% merchandise and about 3% other technical services. For FY2024, the Korea IR Council reported technical services of KRW 78.1bn (including KRW 2.4bn of other items), merchandise sales of KRW 10.0bn and product sales of KRW 14.7bn, for total revenue of KRW 102.9bn.

Value-chain position, customers and end-markets

Value-chain position: Alteogen sits upstream as the technology owner and API (enzyme) supplier. Partners run late-stage clinical development, regulatory filings and commercialisation. Alteogen manages enzyme regulatory files, CMC (chemistry, manufacturing and controls) and supply.

Customer types: - Global innovator pharma: MSD, Sanofi, AstraZeneca/MedImmune, Daiichi Sankyo, GSK/Tesaro, Biogen, Novartis and one undisclosed company

  • Biosimilar and generic majors: Sandoz, Intas

  • Regional partners: Qilu (China), Cristália (Brazil), Kissei (Japan, ALT-L9)

  • Korean hospitals and clinics for Tergase

End-markets: - Oncology: immuno-oncology (PD-1) and ADCs, which make up most of the value today

  • Immunology and neurology: Biogen (felzartamab and others)

  • Multiple modalities under the Novartis options

  • Ophthalmology: anti-VEGF biosimilar

  • Breast and gastric cancer biosimilars

  • Aesthetic and pain-adjunct hyaluronidase: Tergase

  • Prospectively, obesity (ALT-M5)

Strategy

Stated strategic themes (paraphrased from company statements, 2025–2026)

  1. Scale the Hybrozyme franchise. Add licensees and more products per licensee. The goal is six or more additional commercial products by 2030, on top of the three commercial products the company counted in January 2026: Keytruda SC, Anqutuo and Tergase/ALT-L9.

  2. Move from licensing income to sales-based income. Turn Keytruda SC sales milestones (up to US$1bn) and later royalties into recurring revenue. The CEO said in H1 2026 that partner product sales had begun generating income.

  3. Diversify beyond one platform. The CEO stated in October 2026 that the company should not depend on a single platform. KRW 150bn of the October 2026 raise is earmarked for acquiring products and technologies and for R&D. New modalities include RNA (Daishin, August 2026) and the long-acting conjugate platform (ALT-M5).

  4. Bring manufacturing in-house with the Daejeon DS/DP plant, for supply security and margin capture. This also responds to supply-chain politics such as the US BIOSECURE Act, which the founder cited in February 2025.

  5. Governance and capital-markets maturation: a professional CEO, a majority-independent board, an audit committee, an ESG programme, the first dividend, and bonus issues. The KOSPI transfer has been deferred, not abandoned.

Initiatives in the last 24 months

DateInitiativeDetail / target
Feb 2025RCPS raiseKRW 155bn (434,848 shares at KRW 356,433) for a plant, HQ relocation and operations. NH, DB, Kiwoom, KB funds and others subscribed.
2,025Sought external platforms and M&AFounder said "bold investment for the next 10 years". A possible JV with Orion for manufacturing was floated in press (February 2025) and is unconfirmed.
Sep 2025KOSPI transfer processKorea Investment & Securities appointed as lead manager (29 September 2025).
Dec 2025Leadership transitionBoard-centred management model
Dec 2025ALT-B4 option agreementUndisclosed partner; final decision due in 2026
Jan 2026Strategy communication after the royalty sell-offRoyalty term to early 2043. Two or more companies in due diligence. Target of 6+ products by 2030.
Feb 2026Shareholder returnsFirst cash dividend, KRW 371 per share (about KRW 20bn), paid from tax-exempt capital reserves
Mar–Apr 2026"First year of ESG management"Audit committee; majority-independent board; Logblack ESG data platform (16 April 2026); first GRI-based sustainability report planned for 2026
Jul 2026Capital-markets resetKOSPI transfer suspended; 30% bonus issue
Aug 2026ManufacturingKRW 253.2bn Daejeon plant (55.7% of FY2025 equity)
Sep 2026New platformLong-acting conjugate PCT; ALT-M5 data at ObesityWeek, November 2026
Oct 2026Growth capitalKRW 200bn from SkyAlt (CPS and RCPS, KRW 100bn each): KRW 150bn for new products, technology and R&D; KRW 50bn for the plant
Oct 2026SimplificationMerger of Alteogen Biologics into the parent to bring development, regulatory and commercial capabilities in-house

Guidance and medium-term targets

Alteogen does not publish formal quantitative financial guidance. Its qualitative outlook is for continued revenue from milestones and royalties as licenses mature (Q1/Q2 2026 materials). Brokers forecast 2026 operating profit above KRW 300bn (Kormedi, citing the securities industry, July 2026). This compares with H1 2026 operating profit of KRW 73.5bn, which implies a heavy H2 skew that depends on sales milestones and option fees.

Products & Services

Hybrozyme™ platform / ALT-B4 (berahyaluronidase alfa)

AttributeDetail
DescriptionA recombinant human hyaluronidase (a PH20 variant) engineered by domain swapping for better thermal stability and activity. It temporarily breaks down hyaluronan in the subcutaneous extracellular matrix so that large-volume biologics can be given by SC injection.
INNBerahyaluronidase alfa (US suffix for the Merck product: -pmph)
Key IPUS composition patent family expected to run to about 2043. Merck royalties run until early 2043 (company statement, 21 January 2026). European patent granted 10 June 2026. Halozyme's IPR against Alteogen's manufacturing-process patent US 12,221,638 was denied institution.
Target customersGlobal innovator pharma (IO, ADCs, immunology, neurology) and biosimilar developers seeking differentiated SC biosimilars
Pricing modelUpfront or option fees, development, regulatory and sales milestones, tiered royalties, and supply revenue. Disclosed or reported royalty data points: about 2% for Keytruda SC (per Merck's Q3 2025 10-Q as reported by Korean media); "mid-single-digit" for Biogen combination products (Biogen 10-Q); 10% or more for the Sandoz and Intas biosimilar deals (company comments, 2022).
Commercial statusFirst commercial product: Keytruda Qlex™ / Keytruda SC (Merck). Approved in the US (September 2025), EU (November 2025) and Japan (September 2026); 41 countries in total per October 2026 reports. Sales: US$40m in Q4 2025, US$128m in Q1 2026, US$463m in Q2 2026 (Merck).
Recent technical dataMay 2026: ALT-B4 combined with a Becton Dickinson delivery device in animal studies (PDA Miniverse 2026) cut administration time and sped dispersion. June 2026: ALT-B4 co-administered with ADCs (World ADC) suggested improved skin-toxicity and safety markers.
PartnerProduct / scopeStage (latest known)
MSD (Merck & Co.)Keytruda (pembrolizumab) SC, exclusive. Non-exclusive rights for other MSD targets remain under the 2020 agreement.Marketed (Keytruda Qlex / Keytruda SC)
Sanofi2019 license (disclosed in Q2 2026); targets undisclosed—
IntasTwo products (biosimilar SC)Pivotal Phase 1 of a biosimilar SC started (company IR, February 2025)
SandozJoint development of a new hyaluronidase for SC biosimilars (since July 2024)Development
Daiichi SankyoEnhertu (trastuzumab deruxtecan) SCPhase 1 started September 2025
AstraZeneca (MedImmune UK and US)SC formulations of several oncology assets (two agreements)Clinical trials in progress (CEO, February 2026); assets undisclosed
GSK / TesaroDostarlimab (Jemperli) SCDevelopment
BiogenTwo biologics, one being felzartamab (Biogen 10-Q), plus an option on a thirdDevelopment
Undisclosed global pharmaOne SC biologic, worldwide (5 August 2026)Development
NovartisOptions on multiple products and modalitiesOption stage

Tergase® (ALT-BB4) — standalone recombinant human hyaluronidase

Description: A high-purity recombinant human hyaluronidase. It is positioned against animal-derived (bovine or ovine) products and against Halozyme's Hylenex, citing lower injection-site reaction rates (company and Shinhan comparisons).

Approval: Korean MFDS, July 2024.

Indications: Adjunct for dispersion and absorption of injected drugs, and relief of pain and oedema (aesthetic and procedural use).

Channel: Originally Alteogen Healthcare, then Alteogen Biologics after the 2025 merger. Clinic-channel co-promotion with PharmaResearch. Hospital formulary listings went past 40 general hospitals early in launch, with a target of more than 100.

Commercial traction: Korean press (Dealsite, 2026) describes uptake as underwhelming. Revenue is not separately disclosed.

Biosimilars

ProductReference / targetStatusCommercial model
ALT-L9: Eyluxvi® (EU), Eyzenpi® / 아이젠피 (Korea)Eylea (aflibercept); wAMD, RVO macular oedema, DME, myopic CNVEC approval 17 September 2025 (CHMP positive opinion July 2025). Korean MFDS approval May 2026. Saudi Arabia approval Q2 2026. Launch preparation under way.In-house and Alteogen Biologics. Kissei historically partnered for Japan. Future in-house manufacturing at the Daejeon plant.
ALT-L2: Anqutuo / 安曲妥 (China)Herceptin (trastuzumab), IVApproved and launched in China (2024) by QiluRoyalty on net sales (described as industry-average, about 10 years). Qilu and Alteogen are discussing ex-China expansion. Cristália holds Brazil rights.
ALT-LS2Trastuzumab SC (biosimilar plus ALT-B4)Development (historical pipeline)—

NexMab™ ADC platform

ALT-P7: A HER2-targeted ADC for breast and gastric cancer built on site-specific conjugation. It has reached Phase 1 (historical disclosures).

Strategic use: The conjugation know-how now underpins the long-acting conjugate platform. ALT-B4 plus ADC co-administration is being studied (World ADC, June 2026).

NexP™ long-acting fusion platform

ALT-P1: A long-acting human growth hormone (Phase 2 / IIa; Cristália in Brazil received Phase 2 IND approval per February 2025 IR).

Long-acting conjugate platform and ALT-M5 (obesity)

Platform: It extends the site-specific antibody conjugation technology to combine several active molecules into one conjugate and extend half-life. The PCT filing was completed in September 2026.

ALT-M5: A once-monthly incretin fusion protein. Animal studies suggest monthly dosing is feasible and that weight regain after stopping is suppressed. Data are due at ObesityWeek 2026 (Washington, D.C., 14–17 November 2026). The asset is preclinical, and pricing and partnering are not disclosed.

Manufacturing / CDMO capability (planned)

Daejeon Dungok plant: KRW 253.2bn over about 3 years for drug substance and drug product manufacturing, completion by 30 September 2028. Planned products are ALT-B4 and ALT-L9.

  • Former CEO Park said in August 2025 that the Korean site would supply Keytruda SC enzyme for all markets except the US, with the US supplied through a local CMO.

  • Brokers speculate about future third-party CDMO revenue. This is not a company commitment.

Financial Detail

Group Entities

EntityOwnershipRoleStatus

ALTEOGEN Inc. (parent)

Listed

R&D, licensing, ALT-B4 regulatory and supply management, corporate

Operating

Alteogen Biologics Inc. (formerly Altos Biologics)

62.89% (end-2025; book value about KRW 89bn)

ALT-L9 global clinical development and regulatory work. Biosimilar sales and marketing, inherited from the absorbed Alteogen Healthcare. CEO Ji Hee-jung.

Being merged into the parent (announced 6 October 2026; ratio 1:0.1679581; 600,477 new parent shares; completion targeted for December 2026). A planned standalone IPO was dropped in July 2026 amid "duplicate listing" rules.

Alteogen Healthcare

51.5% at end-2024

Tergase and growth-hormone/adhesion-barrier marketing

Absorbed by Altos Biologics in April 2025

Revenue type (KRW Bn)

Revenue type (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Technical services (licensing / ALT-B4, incl. other)

———78.1—

Merchandise sales

———10.0—

Product sales

———14.7—

Total revenue

38.728.896.5102.9215.9

Income Statement and Per-Share Data

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Revenue

38.728.896.5102.9215.9

Gross profit

———64.1165.6

Operating income

-15.2-29.4-9.725.4106.9

Net income

-11.6-10.1-3.660.7144.3

Dividend per share (KRW)

0000371

Margin Analysis (%)

Ratio (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

———62.376.7

Operating margin

-39.3-102.1-10.124.749.5

Net margin

-30.0-35.1-3.759.066.8

Revenue growth YoY

—-25.6235.16.6109.9

Income Statement

Metric (KRW Bn)Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026

Revenue

83.718.649.064.571.668.8

Operating income

60.9-0.426.719.639.334.1

Net income

83.0-34.322.073.671.330.0

Balance Sheet

Metric (KRW Bn)FY2025

Total assets

697.9

Total liabilities

244.3

Total equity

453.6

Cash Flow

Metric (KRW Bn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow

-9.5-17.9-7.853.0124.1

Dividends paid

00000

Margin Analysis (%) (FY2023–FY2025)

RatioFY2023FY2024FY2025

ROE (%)

——29.5

ROA (%, on year-end assets)

——20.7

Total liabilities / equity (%)

——53.9

Current ratio, separate basis (%)

824.5729.6256.3

Revenue source

Revenue sourceCounterparty domicileEnd-market geographyDirection

MSD milestones and royalties (Keytruda SC)

US (MSD International / Merck & Co.)

US-led (October 2025 launch), Japan (approved September 2026), EU (constrained in Germany plus eight countries by injunctions)

Fastest growing

AstraZeneca / MedImmune upfronts and milestones

UK and US

Global

Event-driven

Daiichi Sankyo

Japan

Global

Development milestones

GSK / Tesaro, Biogen, Novartis, undisclosed partner

US / Switzerland / undisclosed

Global

Upfronts in 2026, milestones later

Sandoz, Intas

Switzerland, India

Global biosimilar markets

Development

Anqutuo royalties (Qilu)

China

China

Growing (cited in FY2025 results)

Tergase and ALT-L9 product sales

Korea / EU / Saudi Arabia

Korea and Europe

Early stage

Share Price & Returns

HorizonPerformanceBasis

1-year

About –25% to –35%

KRW 458,000 on 30 September 2025 (pre-bonus) is about KRW 352,300 adjusted, versus about KRW 250,000 in late September / early October 2026

3-year

Strongly positive, roughly +450% to +700% (not precisely verified)

Pre-bonus trading of about KRW 37,000–60,000 in H2 2023 versus about KRW 325,000 on a pre-bonus-equivalent basis today

Market Valuation

Metric (KRW trillion)Dec 2022Nov 2024Dec 2025Jan 2026Oct 2026

Market capitalisation

2.0317.624.325.917.4

Valuation Multiples

MultipleAlteogenComment

P/E (TTM)

About 88–90x

Butler shows 90.0x; derived TTM net income about KRW 196.9bn

Forward P/E (fPER)

About 57x

Butler consensus

EV/Sales (TTM)

About 68x

Assumes EV close to market cap (net cash not fully disclosed)

EV/EBITDA (TTM)

About 130–145x

EBITDA close to operating income (about KRW 120bn TTM)

P/B

About 32x

Butler

Analyst Ratings & Targets

BrokerRatingTarget (KRW)DateBasis

Shinhan Investment

Buy

540,000

Sep 2026

Novartis deal; up to about 10 compounds

Daishin Securities

Buy

450,000 (from 410,000)

3 Sep 2026

rNPV-DCF; fair value KRW 31.4tn; 2 new deals a year assumed

Daol Investment

Not rated

—

3 Sep 2026

Platform scalability

Kiwoom Securities

Commentary

—

22 Jan 2026

Flagged the 2% royalty as an "uncomfortable truth"

Consensus

—

About 438,000 (9 brokers, Butler) or 458,000 (Investing.com)

Sep–Oct 2026

Targets are mostly post-bonus; some may not be fully adjusted

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

0000371

Dividend total (KRW Bn)

000020

Analyst Conclusions

Management guidance and consensus

Alteogen gives no quantitative guidance. Management expects continued milestone and royalty inflows, more licensing deals (two or more companies were in due diligence as of January 2026, and three deals followed), six or more additional commercial products by 2030, and diversification through the KRW 200bn growth capital. The sell-side 2026 operating profit expectation is above KRW 300bn. Against H1 2026 operating profit of KRW 73.5bn, that requires a very strong H2 from Keytruda SC sales milestones, Novartis option economics and the August 2026 deal upfront. Risk to consensus: elevated.

Bull case

  1. The Keytruda SC volume ramp outruns the low royalty. Sales of US$463m in Q2 2026 rose about 262% quarter on quarter. If the 30–40% conversion Merck targets is reached on a franchise of about US$30–35bn, up to US$1bn of sales milestones could arrive by about 2028–2029, followed by royalties to 2043.

  2. Partner flywheel. Four deals in 2026, including Novartis' multi-product structure worth up to US$3.2bn. Several partner programmes are already in the clinic: Enhertu SC Phase 1 and AstraZeneca assets. This builds a pipeline of royalty-bearing products for 2028–2032.

  3. IP momentum in key forums. PTAB invalidations, the UK revocation, the denied IPR on Alteogen's process patent and the European ALT-B4 patent grant support Alteogen's long-term freedom to operate in the US, the largest market.

Bear case

  1. Europe is now a meaningful hole. Keytruda SC is enjoined in Germany plus eight countries. If the US D.N.J. case goes against Merck, a settlement or license fee could dilute Alteogen's economics or delay US sales milestones.

  2. Economics below perception. About 2% royalties, confidential upfronts and an option-heavy Novartis structure mean headline deal values materially overstate risk-adjusted cash flows. The market's reactions in January and September 2026 show these gaps recur.

  3. Valuation. About 88x TTM P/E and about 32x book leave little margin for error while capex (KRW 253bn) and diversification spending (KRW 150bn) rise and preferred-share dilution builds.

Catalysts and monitorables (next 12 months)

13 Nov 2026: Q3 2026 results (recognition of the first sales milestone; revenue mix).

14–17 Nov 2026: ALT-M5 obesity data at ObesityWeek.

19 Nov 2026: Munich appeal hearing on the German preliminary injunction.

Q4 2026: Merck's response to the Hague judgment (appeal or stay); the D.N.J. ruling after the 31 July 2026 argument.

Dec 2026: Completion of the Alteogen Biologics merger; plant groundbreaking.

Rolling: Further Keytruda SC sales milestones (watch Merck quarterly SC sales). Novartis option exercises. Additional licenses. Enhertu SC and AstraZeneca clinical updates. Eyluxvi European launch. Possible return to the KOSPI transfer agenda.

Concluding analyst verdict

Alteogen has made the hard transition from a platform promise to commercial proof. Its enzyme sits inside Keytruda Qlex, now growing by hundreds of millions of dollars a quarter. Ten global pharma companies have licensed ALT-B4, and the 2025 accounts show what the model can deliver: KRW 215.9bn of revenue, a 49.5% operating margin and KRW 124bn of operating cash flow from a workforce of under 200. Recent PTAB, UK and patent-office outcomes favour the company's US position and IP durability. The 2026 run of four licenses, especially Novartis' multi-product option, argues that big pharma views ALT-B4 as a credible second source to Halozyme's ENHANZE.

Three facts temper the thesis. First, the Merck royalty is low, at about 2%, so the value of the flagship asset lies largely in up to US$1bn of sales milestones and in volume, not rate. Second, Halozyme's MDASE estate has now won injunctions in nine European countries, and the US merits case is unresolved. A settlement between Merck and Halozyme, which we see as a plausible end-state, could carry costs that flow through to Alteogen's economics, depending on contractual indemnities that are not publicly disclosed. Third, the company is reinvesting heavily in a plant and in diversification at a time when its earnings remain episodic. It has also chosen confidentiality on most deal terms, which repeatedly produces sharp gaps between expectations and reality.

Net assessment: Alteogen is a strategically important, profitable, IP-rich platform whose medium-term cash generation is visible but whose valuation already capitalises substantial pipeline success. Our stance is constructive on the business and neutral to cautiously positive on the equity. The key swing factors over the next 12 months are the US litigation outcome, the pace of Keytruda SC conversion outside the enjoined European markets, and conversion of the Novartis options into named programmes. Investors should size positions for continued event-driven volatility.


It is not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge (disclosed)Compensation (latest disclosed)

Dr. Park Soon-jae (박순재)

Founder, Chairman, Inside Director, Board Chair; largest shareholder

Co-founded 2008; CEO about 2010/11 to 26 December 2025

PhD in Biochemistry, Purdue; MIT postdoc; LG Life Sciences; Hanwha Petrochemical; chaired a pharmaceutical company in 2009–10

Born 22 December 1954 (71)

Not among the top-5 earners in H1 2025 (Smart Today). Full proxy-style figures not disclosed.

Dr. Tae-Yon Chun (전태연)

President & CEO, Inside Director

Joined September 2020 as EVP (Business Development and IR); CEO since 26 December 2025

PhD in Biochemistry, University of Wisconsin; JD, Indiana University; US patent attorney; led the ALT-B4 licensing deals

Born 1965 (about 61)

H1 2025: KRW 1.862bn total (KRW 100.5m salary plus KRW 1.761bn from stock-option exercises). Held 7,200 shares (0.01%) in December 2025.

Kim Hang-yeon (김항연)

EVP & CFO, Inside Director

——

Born 1965 (per statbase)

—

Dr. Vivek Shenoy

Chief Business Development Officer

————

Dr. Kyuwan Kim

SVP, Head of New Drug Development

————

Kang Sang-woo

SVP, Management Support

————

Dr. Ji Hee-jung (지희정)

CEO, Alteogen Biologics

Since about December 2020 (co-CEO of Altos at formation)

PhD in Biochemistry, Purdue; LG Chem; Green Cross; President of Genexine's research institute

——

“—” = not publicly disclosed.

Major Shareholders

HolderStakeSource / date

Park Soon-jae (personal)

About 19.07–19.1% (10.21m shares, pre-bonus)

H1 2025 report; FY2025 business report; Hankyung, March 2026

Park Soon-jae and related parties

20.33%

Daishin, May 2026

Hyung In-woo (Smart & Growth) and related parties

5.08% (Hyung personally about 5.05%)

Daishin, May 2026; Hankyung, March 2026

Chung Hye-shin (co-founder)

0.8% (June 2024), after selling 1.6m shares in March 2024

Wikipedia / Hankyung

Park Su-min

0.5% (June 2024)

Wikipedia

Minority shareholders

70.05% (247,613 holders)

FY2025 business report (via etfshopping)

Foreign ownership

About 13.8–14.4%

KRX data, January 2026

SkyAlt (National Growth Fund / Skylake vehicle)

KRW 100bn CPS plus KRW 100bn RCPS (being issued October 2026)

Dailypharm / Seoul Economic Daily, October 2026

Competitive Landscape

Competitors by Segment

Business lineCompetitorOfferingRelative positioning

SC conversion enzyme platform

Halozyme Therapeutics (US)

ENHANZE® (rHuPH20); MDASE™ patents; Hypercon™ (Elektrofi, acquired November 2025); Surf Bio (acquired December 2025)

Incumbent leader with about 10 approved partnered products (Darzalex SC, Phesgo, Vyvgart Hytrulo and others). Litigation adversary.

SC conversion (device / formulation alternatives)

Enable Injections (enFuse® on-body delivery)

Large-volume wearable SC delivery

Complementary or substitute for some molecules

SC conversion (formulation)

Xeris Biopharma (XeriJect™)

High-concentration non-aqueous formulation

Niche substitute

SC conversion (in-house)

Big pharma high-concentration formulations (e.g., in-house SC versions without hyaluronidase)

Formulation science

Partners can bypass enzymes for low-volume doses

Aflibercept biosimilars

Samsung Bioepis (Opuviz), Celltrion (Eydenzelt), Amgen (Pavblu), Biocon/Viatris (Yesafili), Sandoz (Afqlir), Formycon, Alvotech/Teva, Sam Chun Dang (SCD411)

Eylea biosimilars

Crowded. Alteogen is a later entrant with a smaller commercial footprint.

Trastuzumab biosimilars (China)

Henlius and other Chinese and global biosimilar makers

Herceptin biosimilars

Qilu's Anqutuo is one of several

Standalone hyaluronidase (Korea)

Animal-derived hyaluronidases (multiple domestic suppliers); Halozyme Hylenex (US)

Dispersion adjunct

Tergase is differentiated on purity and lower ISR (injection-site reaction)

Korean platform biotechs (capital-market peers)

LigaChem Biosciences (ADC), ABL Bio (Grabody), D&D Pharmatech, Voronoi

Licensing-led platforms

Compete for KOSDAQ biotech capital and licensing attention

Peer Comparison FY2025

MetricAlteogen (FY2025)Halozyme (FY2025)

Revenue

KRW 215.9bn (about US$157m)

US$1,396.6m

Revenue growth YoY

+109.9%+38%

Royalty revenue

Small (Anqutuo; Keytruda SC still in the milestone phase)

US$868m (+52%)

Operating margin

49.5%

EBITDA US$657.6m, about 47% of revenue)

Net margin

66.8%

22.7% (net income US$316.9m)

R&D intensity

Not disclosed (FY)

—

2026 guidance

None published

Revenue US$1.71–1.81bn; royalties US$1.13–1.17bn

Company Snapshot

$151.9M

Revenue

30

Employees

$12,600M

Market Cap

2008

Founded

Daejeon, South Korea

Headquarters

SWOT Analysis

Strengths

  • Commercial validation in the world's top drug. Keytruda Qlex was FDA-approved on 19 September 2025 for 38 indications. Sales rose to US$463m in Q2 2026 from US$40m in Q4 2025 (Merck).
  • Deep partner bench. Ten licensees, with KRW 16tn of cumulative headline value. Four new deals were signed in 2026 alone: Tesaro, Biogen, the undisclosed partner and Novartis (US$3.223bn).
  • Profitability. FY2025 operating margin of 49.5% and net income of KRW 144.3bn. Operating cash flow of KRW 124.1bn (OpenDART).
  • Long IP runway. ALT-B4 US protection and Merck royalties run to early 2043. The European patent was granted in June 2026. Halozyme's IPR on US 12,221,638 was denied.
  • Balance sheet capacity. FY2025 equity of KRW 453.6bn, plus KRW 155bn of RCPS (2025) and KRW 200bn from SkyAlt (2026), funds the plant and diversification without heavy borrowing.
  • US IP wins. PTAB final decisions on 12 and 18 May 2026 found Halozyme's '600 and '262 patents unpatentable. Halozyme consented to EP622 revocation in the UK and was ordered to pay indemnity costs.

Weaknesses

  • Low headline royalty. About 2% on Keytruda SC (per Merck's 10-Q as reported) against 4–5% market expectations. This caused a 22.35% one-day drop on 21 January 2026.
  • Earnings lumpiness. Quarterly revenue swung from KRW 83.7bn (Q1 2025) to KRW 18.6bn (Q2 2025). Q2 2025 had an operating loss of KRW 0.4bn.
  • Single-platform concentration. About 88% of Q2 2026 revenue came from ALT-B4 technical services. The CEO himself flagged single-platform dependence in October 2026.
  • Weak self-commercialisation record. Korean press describes Tergase and Eyzenpi traction as underwhelming (Dealsite, 2026), and product sales are not material.
  • Outsourced supply. ALT-B4 is currently made by external CMOs. The own plant arrives only in September 2028.
  • Disclosure opacity. Royalty rates, upfronts (Daiichi, Novartis, undisclosed partner) and option terms are kept confidential. This produces expectation gaps, such as the 2–3 September 2026 sell-off after the Novartis announcement.

Opportunities

  • Up to US$1bn of Keytruda SC sales milestones before royalties. The first US$25m arrived in August 2026.
  • Novartis multi-product options. Up to about 10 compounds (Shinhan), with option fees and milestones as programmes advance.
  • ADC and immunology expansion. Enhertu SC (Phase 1), AstraZeneca oncology assets, Biogen felzartamab, and ALT-B4 + ADC skin-toxicity data (June 2026).
  • In-house manufacturing. Margin capture on ALT-B4 supply, ex-US Keytruda SC enzyme supply, and potential CDMO revenue.
  • New platforms. Long-acting conjugate and ALT-M5 monthly obesity therapy (ObesityWeek, November 2026). RNA modalities (Daishin).
  • KOSPI transfer optionality if KOSPI 200 weighting economics improve. The company estimated the weight at about 0.3% in July 2026, versus about 1% earlier.

Threats

  • European injunctions. Germany (Munich preliminary injunction, 4 December 2025; appeal hearing 19 November 2026) and eight countries under the Hague judgment of 7 October 2026.
  • US litigation. Halozyme v. Merck in D.N.J. covers 15 MDASE patents. Twelve were subject to PGR petitions; the outcome is pending.
  • Keytruda IV loss of exclusivity in 2028. IV biosimilars may compress the price premium for SC.
  • Competitive response from Halozyme. Expanded technology through Elektrofi/Hypercon and Surf Bio, and 2026 revenue guidance of US$1.71–1.81bn.
  • Partner concentration. Merck drives most near-term value. Any change in MSD's SC strategy would be material.
  • Capital-markets volatility. The stock fell from KRW 569,000 (November 2025, pre-bonus) to about KRW 250,000 after the bonus issue (about KRW 325,000 on a pre-bonus basis), roughly –43%. The investor base is retail-heavy, with 70% minority ownership.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Apr 2025Halozyme sues Merck in D.N.J., alleging that SC Keytruda infringes 15 MDASE patentsOpens the main US IP overhang
Apr 2025Altos Biologics absorbs Alteogen HealthcareStreamlines subsidiaries
Jun 2025PTAB institutes Merck's PGR reviews of MDASE patents. The stock rises about 9% (4 June).Early signal favourable to Merck/Alteogen
Jul 2025Second-largest shareholder Hyung In-woo raises his stake and calls for a KOSPI transferActivist pressure
28 Jul 2025CHMP positive opinion for Eyluxvi (ALT-L9)Biosimilar validation
13 Aug 2025Founder announces a plan for a KRW 250bn domestic plant to be self-fundedSupply-chain strategy
17 Sep 2025EC approves EyluxviFirst in-house biosimilar approval
19 Sep 2025FDA approves Keytruda Qlex (38 indications)First ALT-B4 commercial product
Sep 2025Daiichi Sankyo starts Enhertu SC Phase 1Second partner programme in the clinic
29 Sep 2025Korea Investment & Securities appointed for the KOSPI transferListing upgrade process begins
1 Oct 2025US$25m MSD approval milestone disclosed (invoiced 30 September 2025)Drives a Q3 2025 operating profit of KRW 26.7bn
Oct 2025Keytruda Qlex US launchSales-milestone clock starts
14 Nov 2025Q3 2025: revenue KRW 49.0bn (+900% YoY); 9M revenue KRW 151.4bnRecord 9M
18 Nov 2025All-time-high share price of KRW 569,000Market-cap peak period
Nov 2025EU approves Keytruda SCEuropean commercialisation (later partially blocked)
4–5 Dec 2025Munich court grants Halozyme a preliminary injunction against Keytruda SC in Germany; Alteogen falls about 12% intraday (down as much as 18.8%)First adverse court ruling
8 Dec 2025EGM approves the KOSPI transfer (about 98% in favour)—
Dec 2025Halozyme files IPR against Alteogen's ALT-B4 manufacturing patentDirect attack on Alteogen IP (later denied)
26 Dec 2025Founder steps back; Chun becomes CEO. Undisclosed ALT-B4 option signed.Leadership transition
15–16 Jan 2026At JPM, the CEO signals a near-term deal "of similar scale" to prior deals; the stock rebounds 9.5%Expectations raised
20 Jan 2026GSK/Tesaro deal (US$285m)Below the market's hoped-for US$1bn+ size
21 Jan 2026Merck's 2% royalty rate becomes widely known; the stock falls 22.35% to KRW 373,500; Shinhan cuts its target from KRW 730k to 570kMajor de-rating; company posts a statement (royalty term to 2043; 2+ companies in due diligence)
29–30 Jan 2026Alteogen drops to third by KOSDAQ market capSentiment trough
2 Feb 2026Preliminary separate-basis FY2025: revenue KRW 202.1bn, operating income KRW 114.8bn—
11 Feb 2026First dividend, KRW 371 per shareShareholder-return milestone
Feb 2026UK Patents Court finding against Halozyme's position (preliminary)IP momentum
27 Feb 2026FY2025 consolidated: revenue KRW 215.9bn, operating income KRW 106.9bn, net income KRW 144.3bnRecord year
23 Mar 2026FY2025 business report filed—
25 Mar 2026Biogen license (US$20m upfront, up to US$579m incl. US$10m second-product start)Fifth / sixth disclosed licensee
31 Mar 2026AGM: audit committee created, majority-independent board; activist opposition to CFO re-electionGovernance
Apr 2026Permanent US J-code for Keytruda Qlex; ESG programme launched (16 April)Reimbursement catalyst
8 May 2026Q1 2026: revenue KRW 71.6bn (–14.5% YoY), operating income KRW 39.3bnBase effect from AstraZeneca
12–18 May 2026PTAB final decisions find Halozyme's '600 and '262 patents unpatentable; '685 institution denied (discretionary)US IP win for Merck
May 2026Korean approval of Eyzenpi (ALT-L9); Halozyme consents to EP622 revocation in the UK; BD device data—
10 Jun 2026ALT-B4 European patent granted; stock +11% for the weekIP strengthening
17 Jun 2026UK court orders Halozyme to pay indemnity costs—
Jun 2026CEO says at BIO USA that the KOSPI transfer is being reconsidered; World ADC data—
14 Jul 2026Hague court rejects Halozyme's preliminary injunction for Denmark/SwedenTemporary European relief
16 Jul 2026KOSPI transfer suspended; 30% bonus issue (record date 6 August, listing 26 August)Capital-markets reset
31 Jul 2026D.N.J. oral argument scheduled in Halozyme v. MerckOutcome not yet reported
5 Aug 2026ALT-B4 license with undisclosed pharma (up to US$365m)Third deal of 2026
7 Aug 2026Q2 2026: revenue KRW 68.8bn (+269.5% YoY), operating income KRW 34.1bn; Keytruda Qlex Q2 sales US$463mSales-linked income begins
21 Aug 2026KRW 253.2bn Daejeon plant approvedCapex step-up
26 Aug 2026H1 2026 semi-annual report filed—
31 Aug 2026First Keytruda SC sales milestone (US$25m / about KRW 34.4bn)Q3 2026 revenue support
2 Sep 2026Novartis option and license (up to US$3.223bn); stock touches KRW 329,000 then closes KRW 298,500Largest headline deal
3 Sep 2026Daishin raises target to KRW 450,000; Shinhan to KRW 540,000—
Sep 2026Keytruda SC approved in Japan; long-acting platform PCT; ALT-M5—
6 Oct 2026KRW 200bn SkyAlt financing; Alteogen Biologics mergerDiversification capital
7 Oct 2026Hague judgment: EP622 valid and infringed; Keytruda SC enjoined in 8 countriesMaterial European setback; Merck to appeal

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue Type: Total revenue rose from KRW 38.7 Bn in FY2021 to KRW 215.9 Bn in FY2025.
ALTEOGEN Inc. — Revenue Type
Series (KRW Bn)FY2021FY2022FY2023FY2024FY2025
Total revenue38.728.896.5102.9215.9
Technical services (licensing / ALT-B4, incl. other)———78.1—
Merchandise sales———10—
Product sales———14.7—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.